Leukocytes as carriers for targeted cancer drug delivery

Bibliography

• Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011;331:1559-64
   PubMed Web of Science ®Google Scholar
• Schroeder A, Heller DA, Winslow MM, et al. Treating metastatic cancer with nanotechnology. Nat Rev Cancer 2011;12(1):39-50
   PubMed Web of Science ®Google Scholar
• Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000;11:1029-33
   PubMed Web of Science ®Google Scholar
• Prabhakar U, Maeda H, Jain RK, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 2013;73(8):2412-17
   PubMed Web of Science ®Google Scholar
• Christofori G. New signals from the invasive front. Nature 2006;441(7092):444-50
   PubMed Web of Science ®Google Scholar
• Brown JM. The hypoxic cell. Cancer Res 1999;59:5863-70
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-9
   PubMed Web of Science ®Google Scholar
• Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012;63:185-98
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2(12):751-60
   PubMed Web of Science ®Google Scholar
• Kim SH, Jeong JH, Chun KW, Park TG. Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate. Langmuir 2005;21(19):8852-7
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Jon S, Khademhosseini A, et al. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 2004;64(21):7668-72
   PubMed Web of Science ®Google Scholar
• Zhang L, Gu FX, Chan JM, Wang AZ. Nanoparticles in Medicine: therapeutic Applications and Developments. Clin Pharmacol Ther 2008;83:761-9
   PubMed Web of Science ®Google Scholar
• Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008;5(4):505-15
   PubMed Web of Science ®Google Scholar
• Gu F, Zhang L, Teply BA, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA 2008;105(7):2586-91
   PubMed Web of Science ®Google Scholar
• Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2012;64:206-12
   Web of Science ®Google Scholar
• Bala I, Hariharan S, Kumar MN. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst 2004;21(5):387-422
   PubMed Web of Science ®Google Scholar
• Calvo P, Remuñan-López C, Vila-Jato JL, Alonso MJ. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res 1997;14(10):1431-6
   PubMed Web of Science ®Google Scholar
• Hrkach JS, Peracchia MT, Bomb A, et al. Nanotechnology for biomaterials engineering: structural characterization of amphiphilic polymeric nanoparticles by 1H NMR spectroscopy. Biomaterials 1997;18(1):27-30
   PubMed Web of Science ®Google Scholar
• Rancan F, Todorova A, Hadam S, et al. Stability of polylactic acid particles and release of fluorochromes upon topical application on human skin explants. Eur J Pharm Biopharm 2012;80(1):76-84
   PubMed Web of Science ®Google Scholar
• Muzzarelli R, Baldassarre V, Conti F, et al. Biological activity of chitosan: ultrastructural study. Biomaterials 1988;9(3):247-52
   PubMed Web of Science ®Google Scholar
• Felt O, Buri P, Gurny R. Chitosan: a Unique Polysaccharide for Drug Delivery. Drug Dev Ind Pharm 1998;24(11):979-93
   PubMed Web of Science ®Google Scholar
• Mitra S, Gaur U, Ghosh PC, Maitra AN. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release 2001;74(1-3):317-23
   PubMed Web of Science ®Google Scholar
• Hu Y, Jiang X, Ding Y, et al. Synthesis and characterization of chitosan–poly(acrylic acid) nanoparticles. Biomaterials 2002;23:3193-201
   PubMed Web of Science ®Google Scholar
• Guo R, Zhang L, Jiang Z, et al. Synthesis of alginic acid-poly[2-(diethylamino)ethyl methacrylate] monodispersed nanoparticles by a polymer-monomer pair reaction system. Biomacromolecules 2007;8(3):843-50
   PubMed Web of Science ®Google Scholar
• Bangham AD. Liposomes: the Babraham connection. Chem Phys Lipids 1993;64(1-3):275-85
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4(2):145-60
   PubMed Web of Science ®Google Scholar
• Barenholz Y. Doxil® – The first FDA-approved nano-drug: lessons learned. J Control Release 2012;160:117-34
   PubMed Web of Science ®Google Scholar
• Leonard RCF, Williams S, Tulpule A, et al. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet™). Breast 2009;18(4):218-24
   PubMed Web of Science ®Google Scholar
• Lal S, Clare SE, Halas NJ. Nanoshell-enabled photothermal cancer therapy: impending clinical impact. Acc Chem Res 2008;41(12):1842-51
   PubMed Web of Science ®Google Scholar
• Choi M-R, Stanton-Maxey KJ, Stanley JK, et al. A Cellular Trojan Horse for delivery of therapeutic nanoparticles into tumors. Nano Lett 2007;7(12):3759-65
   PubMed Web of Science ®Google Scholar
• Park J-H, Maltzahn von G, Xu MJ, et al. Cooperative nanomaterial system to sensitize, target, and treat tumors. Proc Natl Acad Sci USA 2010;107(3):981-6
   PubMed Web of Science ®Google Scholar
• Minelli C, Lowe SB, Stevens MM. Engineering nanocomposite materials for cancer therapy. Small 2010;6(21):2336-57
   PubMed Web of Science ®Google Scholar
• Libutti SK, Paciotti GF, Byrnes AA, et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res 2010;16(24):6139-49
   PubMed Web of Science ®Google Scholar
• Bardhan R, Lal S, Joshi A, Halas NJ. Theranostic nanoshells: from probe design to imaging and treatment of cancer. Acc Chem Res 2011;44(10):936-46
   PubMed Web of Science ®Google Scholar
• Huang X, El-Sayed IH, Qian W, El-Sayed MA. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J Am Chem Soc 2006;128(6):2115-20
   PubMed Web of Science ®Google Scholar
• Lewinski N, Colvin V, Drezek R. Cytotoxicity of nanoparticles. Small 2008;4(1):26-49
   PubMed Web of Science ®Google Scholar
• Yang W, Thordarson P, Gooding JJ, et al. Carbon nanotubes for biological and biomedical applications. Nanotechnology 2007;18(41):412001
   Web of Science ®Google Scholar
• Chakravarty P, Marches R, Zimmerman NS, et al. Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes. Proc Natl Acad Sci USA 2008;105(25):8697-702
   PubMed Web of Science ®Google Scholar
• Welsher K, Liu Z, Daranciang D, Dai H. Selective probing and imaging of cells with single walled carbon nanotubes as near-infrared fluorescent molecules. Nano Lett 2008;8(2):586-90
   PubMed Web of Science ®Google Scholar
• Liu Z, Chen K, Davis C, et al. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res 2008;68:6652-60
   PubMed Web of Science ®Google Scholar
• Dumortier H, Lacotte S, Pastorin G, et al. Functionalized carbon nanotubes are non-cytotoxic and preserve the functionality of primary immune cells. Nano Lett 2006;6(7):1522-8
   PubMed Web of Science ®Google Scholar
• Cui D, Tian F, Ozkan CS, et al. Effect of single wall carbon nanotubes on human HEK293 cells. Toxicol Lett 2005;155(1):73-85
   PubMed Web of Science ®Google Scholar
• Lam C-W, James JT, McCluskey R, Hunter RL. Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. Toxicol Sci 2004;77(1):126-34
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-34
   PubMed Web of Science ®Google Scholar
• Yang SX. Bevacizumab and breast cancer: current therapeutic progress and future perspectives. Expert Rev Anticancer Ther 2009;9(12):1715-25
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26(20):3358-63
   PubMed Web of Science ®Google Scholar
• Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376(9742):687-97
   PubMed Web of Science ®Google Scholar
• Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006;11:4-12
   PubMed Web of Science ®Google Scholar
• Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010;7(11):653-64
   PubMed Web of Science ®Google Scholar
• Nel A, Xia T, Mädler L, Li N. Toxic potential of materials at the nanolevel. Science 2006;311(5761):622-7
   PubMed Web of Science ®Google Scholar
• Wirtz D, Konstantopoulos K, Searson PC. The physics of cancer: the role of physical interactions and mechanical forces in metastasis. Nat Rev Cancer 2011;11:512-22
   PubMed Web of Science ®Google Scholar
• Mitchell MJ, King MR. Computational and experimental models of cancer cell response to fluid shear stress. Front Oncol 2013;3:1-11
   Google Scholar
• Maheswaran S, Haber DA. Circulating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev 2010;20(1):96-9
   PubMed Web of Science ®Google Scholar
• Yu M, Stott S, Toner M, et al. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol 2011;192:373-82
   PubMed Web of Science ®Google Scholar
• Schmid-Schönbein GW, Usami S, Skalak R, Chien S. The interaction of leukocytes and erythrocytes in capillary and postcapillary vessels. Microvasc Res 1980;19(1):45-70
   PubMed Web of Science ®Google Scholar
• Ley K. Molecular mechanisms of leukocyte recruitment in the inflammatory process. Cardiovasc Res 1996;32:733-42
   PubMed Web of Science ®Google Scholar
• Goldsmith HL, Spain S. Margination of leukocytes in blood flow through small tubes. Microvasc Res 1984;27(2):204-22
   PubMed Web of Science ®Google Scholar
• Firrell JC, Lipowsky HH. Leukocyte margination and deformation in mesenteric venules of rat. Am J Physiol Heart Circ Physiol 1989;256(6 Pt 2):H1667-74
   Google Scholar
• Nobis U, Pries AR, Cokelet GR, Gaehtgens P. Radial distribution of white cells during blood flow in small tubes. Microvasc Res 1985;29(3):295-304
   PubMed Web of Science ®Google Scholar
• Cheung LSL, Raman PS, Balzer EM, et al. Biophysics of selectin-ligand interactions in inflammation and cancer. Phys Biol 2011;8(1):015013
   Google Scholar
• Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991;67(6):1033-6
   PubMed Web of Science ®Google Scholar
• Springer TA. Adhesion receptors of the immune system. Nature 1990;346:425-34
   PubMed Web of Science ®Google Scholar
• Sundd P, Pospieszalska M, Cheung L, et al. Biomechanics of leukocyte rolling. Biorheology 2011;48:1-35
   PubMed Web of Science ®Google Scholar
• Sundd P, Pospieszalska MK, Ley K. Neutrophil rolling at high shear: flattening, catch bond behavior, tethers and slings. Mol Immunol 2013;55(1):59-69
   PubMed Web of Science ®Google Scholar
• Finger E, Puri K, Alón R, et al. Adhesion through L-selectin requires a threshold hydrodynamic shear. Nature 1996;379:266-8
   PubMed Web of Science ®Google Scholar
• Cao TM, Mitchell MJ, Liesveld J, King MR. Stem cell enrichment with selectin receptors: mimicking the pH environment of trauma. Sensors (Basel) 2013;13:12516-26
   PubMed Web of Science ®Google Scholar
• Kansas GS. Selectins and their ligands: current concepts and controversies. Blood 1996;88:3259-87
   PubMed Web of Science ®Google Scholar
• Mitchell MJ, Lin KS, King MR. Fluid shear stress increases neutrophil activation via platelet-activating factor. Biophys J 2014;106(10):2243-53
   PubMed Web of Science ®Google Scholar
• Mitchell MJ, King MR. Shear-induced resistance to neutrophil activation via the formyl peptide receptor. Biophys J 2012;102:1804-14
   PubMed Web of Science ®Google Scholar
• Ding ZM, Babensee JE, Simon SI, et al. Relative contribution of LFA-1 and Mac-1 to neutrophil adhesion and migration. J Immunol 1999;163(9):5029-38
   PubMed Web of Science ®Google Scholar
• Diamond MS. ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J Cell Biol 1990;111(6):3129-39
   PubMed Web of Science ®Google Scholar
• Hughes B, Hollers J, Crockett-Torabi E, Smith CW. Recruitment of CD11b/CD18 to the neutrophil surface and adherence-dependent cell locomotion. J Clin Investig 1992;90:1687-96
   PubMed Web of Science ®Google Scholar
• Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76(2):301-14
   PubMed Web of Science ®Google Scholar
• van Ginhoven TM, van den Berg JW, Dik WA, et al. Preoperative dietary restriction reduces hepatic tumor load by reduced E-selectin-mediated adhesion in mice. J Surg Oncol 2010;102(4):348-53
   PubMed Web of Science ®Google Scholar
• McDonald B, Spicer J, Giannais B, et al. Systemic inflammation increases cancer cell adhesion to hepatic sinusoids by neutrophil mediated mechanisms. Int J Cancer 2009;125:1298-305
   PubMed Web of Science ®Google Scholar
• Barthel SR, Wiese GK, Cho J, et al. Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking. Proc Natl Acad Sci USA 2009;106(46):19491-6
   PubMed Web of Science ®Google Scholar
• Dimitroff CJ, Lechpammer M, Long-Woodward D, Kutok J. Rolling of Human Bone-Metastatic Prostate Tumor Cells on Human Bone Marrow Endothelium under Shear Flow Is Mediated by E-Selectin. Cancer Res 2004;64(15):5261-9
   PubMed Web of Science ®Google Scholar
• Tözeren A, Kleinman HK, Grant DS, et al. E-selectin-mediated dynamic interactions of breast-and colon-cancer cells with endothelial-cell monolayers. Int J Cancer 1995;60:426-31
   PubMed Web of Science ®Google Scholar
• Myung JH, Gajjar KA, Pearson RM, et al. Direct measurements on CD24-mediated rolling of human breast cancer MCF-7 cells on E-selectin. Anal Chem 2011;83(3):1078-83
   PubMed Web of Science ®Google Scholar
• Burdick MM, Chu JT, Godar S, Sackstein R. HCELL is the major E- and L-selectin ligand expressed on LS174T colon carcinoma cells. J Biol Chem 2006;281(20):13899-905
   PubMed Web of Science ®Google Scholar
• Brodt P, Fallavollita L, Bresalier RS, et al. Liver endothelial E-selectin mediates carcinoma cell adhesion and promotes liver metastasis. Int J Cancer 1997;71(4):612-19
   PubMed Web of Science ®Google Scholar
• Biancone L, Araki M, Araki K, et al. Redirection of tumor metastasis by expression of E-selectin in vivo. J Exp Med 1996;183(2):581-7
   PubMed Web of Science ®Google Scholar
• Köhler S, Ullrich S, Richter U, Schumacher U. E-/P-selectins and colon carcinoma metastasis: first in vivo evidence for their crucial role in a clinically relevant model of spontaneous metastasis formation in the lung. Br J Cancer 2010;102(3):602-9
   PubMed Web of Science ®Google Scholar
• Rahn JJ, Chow JW, Horne GJ, et al. MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin Exp Metastasis 2005;22(6):475-83
   PubMed Web of Science ®Google Scholar
• Raman D, Sobolik-Delmaire T, Richmond A. Chemokines in health and disease. Exp Cell Res 2011;317:575-89
   PubMed Web of Science ®Google Scholar
• Balkwill FR. The chemokine system and cancer. J Pathol 2011;226(2):148-57
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Jutila M, Butcher E. Identification of a human peripheral lymph node homing receptor: a rapidly down-regulated adhesion molecule. Proc Natl Acad Sci USA 1990;87:2244-8
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Jutila M, Berg E, Butcher E. Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors. Science 1989;245(4923):1238-41
   PubMed Web of Science ®Google Scholar
• Ridley AJ, Schwartz MA, Burridge K, et al. Cell migration: integrating signals from front to back. Science 2003;302:1704-9
   PubMed Web of Science ®Google Scholar
• McEver RP, Moore KL, Cummings RD. Leukocyte trafficking mediated by selectin-carbohydrate interactions. J Biol Chem 1995;270(19):11025-8
   PubMed Web of Science ®Google Scholar
• Vestweber D, Blanks JE. Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev 1999;79:181-213
   PubMed Web of Science ®Google Scholar
• Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011;147(5):992-1009
   PubMed Web of Science ®Google Scholar
• Bajpai S, Mitchell MJ, King MR, Reinhart-King CA. A microfluidic device to select for cells based on chemotactic phenotype. Technology 2014;02(02):101-5
   Google Scholar
• Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 2010;16(3):133-44
   PubMed Web of Science ®Google Scholar
• Salsman VS, Chow KKH, Shaffer DR, et al. Crosstalk between medulloblastoma cells and endothelium triggers a strong chemotactic signal recruiting T lymphocytes to the tumor microenvironment. PLoS One 2011;6(5):e20267
   PubMed Web of Science ®Google Scholar
• Martinet N, Beck G, Bernard V, et al. Mechanism for the recruitment of macrophages to cancer site. In vivo concentration gradient of monocyte chemotactic activity. Cancer 1992;70(4):854-60
   PubMed Web of Science ®Google Scholar
• Mantovani A. Cancer: inflaming metastasis. Nature 2009;457(7225):36-7
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44
   PubMed Web of Science ®Google Scholar
• Swiston AJ, Gilbert JB, Irvine DJ, et al. Freely suspended cellular “backpacks” lead to cell aggregate self-assembly. Biomacromolecules 2010;11(7):1826-32
   PubMed Web of Science ®Google Scholar
• Swiston AJ, Cheng C, Um SH, et al. Surface functionalization of living cells with multilayer patches. Nano Lett 2008;8(12):4446-53
   PubMed Web of Science ®Google Scholar
• Vasconcellos FC, Swiston AJ, Beppu MM, et al. Bioactive polyelectrolyte multilayers: hyaluronic acid mediated B lymphocyte adhesion. Biomacromolecules 2010;11(9):2407-14
   PubMed Web of Science ®Google Scholar
• Doshi N, Swiston AJ, Gilbert JB, et al. Cell-based drug delivery devices using phagocytosis-resistant backpacks. Adv Mater 2011;23(12):H105-9
   PubMed Web of Science ®Google Scholar
• Preece G, Murphy G, Ager A. Metalloproteinase-mediated regulation of L-selectin levels on leucocytes. J Biol Chem 1996;271(20):11634-40
   PubMed Web of Science ®Google Scholar
• Lee D, Schultz JB, Knauf PA, King MR. Mechanical shedding of L-selectin from the neutrophil surface during rolling on Sialyl Lewis x under flow. J Biol Chem 2007;282(7):4812-20
   PubMed Web of Science ®Google Scholar
• Su SS, Schmid-Schönbein GW. Internalization of formyl peptide receptor in leukocytes subject to fluid stresses. Cel Mol Bioeng 2010;3(1):20-9
   PubMed Web of Science ®Google Scholar
• Loughrey HC, Choi LS, Cullis PR, Bally MB. Optimized procedures for the coupling of proteins to liposomes. J Immunol Methods 1990;132(1):25-35
   PubMed Web of Science ®Google Scholar
• Nobs L, Buchegger F, Gurny R, Allémann E. Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci 2004;93(8):1980-92
   PubMed Web of Science ®Google Scholar
• Donoghue N, Yam PT, Jiang XM, Hogg PJ. Presence of closely spaced protein thiols on the surface of mammalian cells. Protein Sci 2000;9(12):2436-45
   PubMed Web of Science ®Google Scholar
• Lawrence DA, Song R, Weber P. Surface thiols of human lymphocytes and their changes after in vitro and in vivo activation. J Leukoc Biol 1996;60(5):611-18
   PubMed Web of Science ®Google Scholar
• Stephan MT, Moon JJ, Um SH, et al. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med 2010;16(9):1035-41
   PubMed Web of Science ®Google Scholar
• Mitchell MJ, Chen CS, Ponmudi V, et al. E-selectin liposomal and nanotube-targeted delivery of doxorubicin to circulating tumor cells. J Control Release 2012;160:609-17
   PubMed Web of Science ®Google Scholar
• Mitchell MJ, Castellanos CA, King MR. Nanostructured surfaces to target and kill circulating tumor cells while repelling leukocytes. J Nanomater 2012;2012(3):1-10
   Google Scholar
• Mitchell MJ, Wayne E, Rana K, et al. TRAIL-coated leukocytes that kill cancer cells in the circulation. Proc Natl Acad Sci USA 2014;111(3):930-5
   PubMed Web of Science ®Google Scholar
• Badwey JA, Karnovsky ML. Active oxygen species and the functions of phagocytic leukocytes. Annu Rev Biochem 1980;49:695-726
   PubMed Web of Science ®Google Scholar
• Dale DC, Boxer L, Liles WC. The phagocytes: neutrophils and monocytes. Blood 2008;112(4):935-45
   PubMed Web of Science ®Google Scholar
• Choi J, Kim HY, Ju EJ, et al. Use of macrophages to deliver therapeutic and imaging contrast agents to tumors. Biomaterials 2012;33:4195-203
   PubMed Web of Science ®Google Scholar
• Choi M-R, Bardhan R, Stanton-Maxey KJ, et al. Delivery of nanoparticles to brain metastases of breast cancer using a cellular Trojan horse. Cancer Nanotechnol 2012;3(1-6):47-54
   PubMedGoogle Scholar
• Brynskikh AM, Zhao Y, Mosley RL, et al. Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson’s disease. Nanomedicine (Lond) 2010;5(3):379-96
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Li S, Reynolds AD, et al. A Macrophage-nanozyme delivery system for parkinson’s disease. Bioconjug Chem 2007;18(5):1498-506
   PubMed Web of Science ®Google Scholar
• Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release 2010;145(3):182-95
   PubMed Web of Science ®Google Scholar
• Sahay G, Querbes W, Alabi C, et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol 2013;31(7):653-8
   PubMed Web of Science ®Google Scholar
• Hirsch LR, Stafford RJ, Bankson JA, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA 2003;100(23):13549-54
   PubMed Web of Science ®Google Scholar
• Graff CL, Pollack GM. Drug transport at the blood-brain barrier and the choroid plexus. Curr Drug Metab 2004;5(1):95-108
   PubMed Web of Science ®Google Scholar
• Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. Neurotherapeutics 2005;2(1):3-14
   Google Scholar
• Schackert G, Simmons RD, Buzbee TM, et al. Macrophage infiltration into experimental brain metastases: occurrence through an intact blood-brain barrier. J Natl Cancer Inst 1988;80:1027-34
   PubMed Web of Science ®Google Scholar
• Morantz RA, Wood GW, Foster M, et al. Macrophages in experimental and human brain tumors. J Neurosurg 1979;50(3):305-11
   PubMed Web of Science ®Google Scholar
• Smith BR, Ghosn E, Rallapalli H, et al. Selective uptake of single-walled carbon nanotubes by circulating monocytes for enhanced tumour delivery. Nat Nanotechnol 2014;9:481-7
   PubMed Web of Science ®Google Scholar
• Stephan MT, Stephan SB, Bak P, et al. Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. Biomaterials 2012;33(23):5776-87
   PubMed Web of Science ®Google Scholar
• Wong SY, Hynes RO. Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide? Cell Cycle 2006;5(8):812-17
   PubMed Web of Science ®Google Scholar
• Wikman H, Vessella R, Pantel K. Cancer micrometastasis and tumour dormancy. APMIS 2008;116:754-70
   PubMed Web of Science ®Google Scholar
• Zamai L, Ponti C, Mirandola P, et al. NK cells and cancer. J Immunol 2007;178(7):4011-16
   PubMed Web of Science ®Google Scholar
• Nieswandt B, Hafner M, Echtenacher B, Männel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999;59:1295-300
   PubMed Web of Science ®Google Scholar
• Bajénoff M, Breart B, Huang AYC, et al. Natural killer cell behavior in lymph nodes revealed by static and real-time imaging. J Exp Med 2006;203(3):619-31
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3(11):991-8
   PubMed Web of Science ®Google Scholar
• Hartkopf AD, Banys M, Krawczyk N, et al. Bone marrow versus sentinel lymph node involvement in breast cancer: a comparison of early hematogenous and early lymphatic tumor spread. Breast Cancer Res Treat 2012;131:501-8
   PubMed Web of Science ®Google Scholar
• Gerber B, Krause A, Müller H, et al. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol 2001;19:960-71
   PubMed Web of Science ®Google Scholar
• Kubuschok B, Passlick B, Izbicki JR, et al. Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non–small-cell lung cancer. J Clin Oncol 1999;17:19-24
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008;26(21):3621-30
   PubMed Web of Science ®Google Scholar
• Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5(2):157-63
   PubMed Web of Science ®Google Scholar
• Mitchell MJ, King MR. Fluid shear stress sensitizes cancer cells to receptor-mediated apoptosis via trimeric death receptors. N J Phys 2013;15(1):015008
   PubMedGoogle Scholar
• Lopez-Verges S, Milush JM, Pandey S, et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 2010;116(19):3865-74
   PubMed Web of Science ®Google Scholar
• Wing-Han Yuen Q, Zheng YP, Huang YP, et al. In-vitro strain and modulus measurements in porcine cervical lymph nodes. Open Biomed Eng J 2011;5:39-46
   PubMedGoogle Scholar
• Zhang XD, Nguyen T, Thomas WD, et al. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 2000;482(3):193-9
   PubMed Web of Science ®Google Scholar
• Mitchell MJ, King MR. Theme: physical Biology in Cancer. 3. The role of cell glycocalyx in vascular transport of circulating tumor cells. Am J Physiol Cell Physiol 2014;306:C89-97
   Web of Science ®Google Scholar
• Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-904
   PubMed Web of Science ®Google Scholar
• Yan L, Cai Q, Xu Y. The Ubiquitin-CXCR4 Axis Plays an Important Role in Acute Lung Infection-Enhanced Lung Tumor Metastasis. Clin Cancer Res 2013;19(17):4706-16
   PubMed Web of Science ®Google Scholar
• Tucci P, Agostini M, Grespi F, et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci USA 2012;109(38):15312-17
   PubMed Web of Science ®Google Scholar
• Chang C-Y, Lin S-C, Su W-H, et al. Somatic LMCD1 mutations promoted cell migration and tumor metastasis in hepatocellular carcinoma. Oncogene 2012;31(21):2640-52
   PubMed Web of Science ®Google Scholar
• Kim S, Takahashi H, Lin W-W, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009;457(7225):102-6
   PubMed Web of Science ®Google Scholar
• Fidler IJ. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 1975;35:218-24
   PubMed Web of Science ®Google Scholar
• Fidler IJ. Inhibition of pulmonary metastasis by intravenous injection of specifically activated macrophages. Cancer Res 1974;34:1074-8
   PubMed Web of Science ®Google Scholar
• Fidler IJ, Nicolson GL. Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J Natl Cancer Inst 1976;57:1199-202
   PubMed Web of Science ®Google Scholar
• Mitchell MJ, King MR. Unnatural killer cells to prevent bloodborne metastasis: inspiration from biology and engineering. Expert Rev Anticancer Ther 2014;14(06):641-4
   PubMedGoogle Scholar
• Subbiah V, Brown RE, Buryanek J, et al. Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist. Mol Cancer Ther 2012;11(11):2541-6
   PubMed Web of Science ®Google Scholar
• Herbst RS, Eckhardt SG, Kurzrock R, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010;17:2839-46
   Google Scholar
• Chandrasekaran S, McGuire MJ, King MR. Sweeping lymph node micrometastases off their feet: an engineered model to evaluate natural killer cell mediated therapeutic intervention of circulating tumor cells that disseminate to the lymph nodes. Lab Chip 2014;14(1):118-27
   PubMed Web of Science ®Google Scholar